Expanded EU Approval For Roche's Perjeta In Early Stage Breast Cancer
This article was originally published in Scrip
Executive Summary
The European Commission (EC) has approved Roche Holding AG's Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy, for use before surgery in adult patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence.